Affymax (AFFY) wins FDA panel backing of anemia drug
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax (Nasdaq: AFFY) wins FDA panel backing of anemia drug, peginesatide. The vote was 15-1-1.
Shares were halted earlier today ahead of the vote.
Shares were halted earlier today ahead of the vote.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Musalem: strong growth and investment influencing bond market - CNBC
- Deere conference call: 2027 orders up mid-single digits from last year)
- Arctos agrees to buy 10% of Atlanta Falcons at $10.6 billion valuation - Bloomberg
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
